Default company panoramic image
Logo

Otologic Pharmaceutics, Inc. (OPI)

OPI is developing oral therapeutics that address noise-induced hearing loss.

  • Stage Product In Development
  • Industry Other
  • Location Oklahoma City, OK, USA
  • Currency USD
  • Founded January 2009
  • Employees 5
  • Website otologicpharmaceutics.com

Company Summary

Oklahoma-headquartered organization formed specifically to commercialize promising technologies that address novel pharmacological solutions for hearing health. The combined research and business experience of the Hough Ear Institute, Oklahoma Medical Research Foundation and American Biohealth Group, have partnered to form OPI to develop therapeutic agents to treat acute noise induced hearing loss.

Team

  • Default avatar
    Kirk Maples PhD
    Consultant

  • Default avatar
    Richard Gammans PhD MSM
    President and Chief Operating Officer

  • Default avatar
    Clayton Duncan
    Chief Executive Officer

  • Default avatar
    Rick Kopke MD
    Chief Medical Officer

  • Default avatar
    Robert Floyd PhD
    Chief Science Officer

Advisors

  • Default avatar
    Cooley, LLP
    Lawyer
    Unconfirmed
    Default avatar
    Cole and Reed LLP
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    OMRF, INTEGRIS HEALTH, i2E, OCAST
    Unconfirmed
    Default avatar
    Founders- Karlman, Kopke, Floyd
    Unconfirmed
    Default avatar
    Consultants discounted billing rate in exchange for stock
    Unconfirmed